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Toxicity of Radiotherapy 
in Patients With Collagen 
Vascular Disease
Background
A diagnosis of collagen vascular disease (CVD) may predispose to radiotherapy (RT) toxicity. The 
objective of the current study was to identify factors that influence RT toxicity in the setting of CVD.
Methods
A total of 86 RT courses for 73 patients with CVD were delivered between 1985 and 2005. CVD 
subtypes include rheumatoid arthritis (RA; 33 patients), systemic lupus erythematosus (SLE; 13 
patients), scleroderma (9 patients), dermatomyositis/polymyositis (5 patients), ankylosing spondy-
litis (4 patients), polymyalgia rheumatica/temporal arteritis (4 patients), Wegener granulomatosis 
(3 patients), and mixed connective tissue disorders (MCTD)/other (2 patients). Each patient with 
CVD was matched to 1 to 3 controls with respect to sex, race, site irradiated, RT dose (±2 Gray), and
age (±5 years).
Results
There was no significant difference between CVD patients (65.1%) and controls (72.5%) 
experiencing any acute toxicity. CVD patients had a higher incidence of any late toxicity (29.1% vs 
14%; P = .001), and a trend toward an increased rate of severe late toxicity (9.3% vs 3.7%; P = .079). 
RT delivered to the breast had increased risk of severe acute toxicity, whereas RT to the pelvis 
had increased risk of severe acute and late toxicity. RT administered in the setting of scleroderma 
carried a higher risk of severe late toxicity, whereas RT to SLE patients carried a higher risk of 
severe acute and late toxicity.
Conclusions
Although generally well tolerated, RT in the setting of CVD appears to carry a higher risk of late 
toxicity. RT to the pelvis or in the setting of SLE or scleroderma may predispose to an even greater 
risk of severe toxicity. These issues should be considered when deciding whether to offer RT for 
these patients. Cancer 2008;113:648–53. ©2008 American Cancer Society.
Key Words: radiotherapy, collagen diseases, complications, adverse effects.
The decision of whether to offer therapeutic radiotherapy (RT) to patients with collagen vascular 
disease (CVD) continues to be a challenging one. It is believed that CVD may predispose patients 
to increased toxicity, and many practicing oncologists believe that a diagnosis of CVD is a relative 
contraindication to RT. However, to our knowledge, the available literature on this issue has been 
mixed. Early publications were largely case reports of CVD patients with increased toxicity from 
RT.1-8 However, 2 separate matched control studies failed to observe any increased risk of acute 
or late complications in patients with CVD versus patients without CVD.9,10 Other publications 
suggested that patients with nonrheumatoid arthritis CVD,11,12 or patients with specific subtypes of 
CVD, may be at increased toxicity risk.13-15 Further complicating the issue is the finding that some 
commonly prescribed medications, many of which are used in patients with CVD, may alter the 
radiation toxicity profile.16–18 The goals of this matched control study were to determine whether 
patients with CVD were at a higher risk of RT-associated toxicity compared with patients without 
CVD and to identify factors that influence radiation toxicity in the setting of CVD, with particular 
emphasis on medications (antirheumatic drugs, nonsteroidal antiinflammatory drugs [NSAIDs], statins, 
and calcium channel blockers [CCBs]) that when taken concurrently may alter radiation toxicity.
Materials and Methods
After Institutional Review Board approval, 
101 patients with a diagnosis of CVD treated 
in the Department of Radiation Oncology at 
the University of Michigan between 1985 and 
2005 were identified. A total of 116 unique 
RT courses were delivered to these patients. A 
majority of these courses were delivered with 
3-dimensional (3D) conformal techniques. 
Twenty-two cases were excluded because the 
diagnosis of CVD was made after the comple-
tion of RT. Of the remaining 94 RT courses, 8 
courses could not be matched with a control. 
This left an analyzable sample of 86 CVD RT 
courses for 73 unique patients. Thirty-three 
patients had rheumatoid arthritis (RA), 13 
had systemic lupus erythematosus (SLE), 9 
had scleroderma, 5 had dermatomyositis/poly-
myositis, 4 had ankylosing spondylitis, 4 had 
polymyalgia rheumatica/temporal arteritis, 
3 had Wegener granulomatosis, and 2 had 
mixed connective tissue disorders (MCTD)/
other. Neither polymyalgia rheumatica/tem-
poral arteritis nor Wegener granulomatosis 
are defined as a CVD; however, their inclusion 
was based on the systemic vasculitis noted with 
these diseases and its potential impact on RT 
toxicity. The mean age of the patients at time 
of RT was 58.2 years (range, 23-84 years) and 
the majority of patients were women (73.3%). 
Sixty patients received only a single RT course, 
with 13 patients receiving 2 RT courses in this 
dataset. Their medical records were reviewed 
for the following characteristics: age, sex, race, 
CVD type and activity, date of CVD diagnosis, 
concurrent medications, cancer diagnosis, 
chemotherapy treatment details, site and dose 
schedule of RT, acute and late toxicity, pattern 
of failure, and survival.
Of the total 86 RT courses, 15 were delivered 
to the thorax, 14 to the skin, 12 to the head and 
neck, 11 to bone, 11 to the pelvis, 8 to the breast, 
6 to total body, 4 to the central nervous system, 
4 to the abdomen, and 1 to an extremity. 
Each CVD patient was then matched with a 
control patient without CVD for sex, race, 
site of disease treated by RT, dose delivered
(±2 Gray [Gy]), and age at time of RT delivery
(±5 years). For CVD patients with many
matching controls, the controls with the smallest
difference with regard to RT dose and age at 
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RT were chosen, with importance placed on minimizing the difference in 
RT dose over the difference in age at RT. An attempt was made to find 
3 matching controls for each CVD RT course. Fifty-nine courses were 
matched to 3 controls, 18 courses were matched to 2 controls, and 9 
courses were matched to a single control.
Acute toxicity was defined as toxicity from the time of commencement of 
RT through Day 90 after treatment and was scored using the Radiation 
Therapy Oncology Group (RTOG) common toxicity criteria.19 Late 
toxicity was defined as occurring after Day 90 posttreatment, and was 
scored according to the RTOG/European Organization for Research and 
Treatment of Cancer (EORTC) late radiation morbidity scoring schema.20 
Severe acute or late toxicity was defined as ≥grade 3. 
Because this is a match-pairs, case-control analysis, conditional logistic 
regression techniques were used. Because sex, age at RT, anatomic site 
treated, and RT dose were matched for by the design, these covariates 
were not adjusted for in the modeling process because their impact has 
been adjusted for by the study design. The remaining covariates of interest 
were as follows: concurrent infusional chemotherapy administration, and 
the use of steroids, NSAIDS, statins, CCBs, antimalarial antirheumatic 
drugs, and oral cytotoxic antirheumatics. Many of the medications apply 
only to the CVD cases and could not be adjusted for in the overall model. 
The medication list is therefore most appropriately used to help predict 
toxicity in the CVD group separately. 
Overall crude rates for toxicity are reported by the anatomic site of RT 
delivery and by CVD subtype of the cases. Although these rates are 
instructive, formal comparison at the matched case-control level has not 
been attempted because of the small sample size. Formal comparisons 
were limited to the entire population. P values ≤.05 are considered 
statistically significant. 
There were 4 endpoints of interest: any acute toxicity, severe acute 
toxicity, any late toxicity, and severe late toxicity.
Results
Acute Toxicity
With a median follow-up time of 1.3 years for each group, overall, there 
was no significant difference noted with regard to the incidence of acute 
toxicity between CVD and control cases, with 65.1% of CVD patients 
experiencing any acute toxicity, compared with 72.5% of control patients 
(Table 1). The incidence of severe acute toxicity was similar in both 
groups (10.5% vs 10.4%).
Late Toxicity
Overall, patients with a CVD diagnosis had a significantly higher 
incidence of any late toxicity (29.1% vs 14%; P =.001), with a trend toward 
increased severe late toxicity (9.3% vs 3.7%; P =.079) (Table 1).          
Table 1. Acute and Late Toxicity by CVD Status
Toxicity Grade Any Severe
Frequency
(percent) 0 1 2 3 4 5 P† P†
Acute Toxicity*
  CVD cases 30 (34.9) 19 (22.1) 28 (32.6)   9 (10.5) 0 0 — —
  Control Cases 61 (27.5) 63 (28.4) 75 (33.8) 23 (10.4) 0 0 .97 .075
Late Toxicity‡
  CVD cases 61 (70.9) 10 (11.6)   7 (8.1)   4 (4.7) 2 (2.3) 2 (2.3) — —
  Control Cases 191 (86.0) 14 (6.3)   9 (4.1)    7 (3.2)  1 (0.5) 0 .0010 .079
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, and 
was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† Exact P value was derived from conditional logistic regression analysis.
‡ Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to
the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20
Table 2. Acute and Late Toxicity by Anatomic Site of 
Radiotherapy Delivery
Frequency
(Percent) Acute toxicity grade*
0 1 2 3 4 5
Bone
  Cases (n = 11)  11 (100.0)   0   0 0 0 0
  Controls (n = 28)  20 (71.4)    4 (14.3)    4 (14.3)  0  0  0
Breast
  Cases (n = 8)    1 (12.5)    1 (12.5)    4 (50.0)  2 (25.0)  0  0
  Controls (n = 20)    0    6 (30.0)  14 (70.0)  0  0  0
Head and neck 
  Cases (n = 12)    0    4 (33.3)    6 (50.0)  2 (16.7)  0  0
  Controls (n = 32)    5 (15.6)    8 (25.0)  12 (37.5)  7 (21.9)  0  0
Pelvis 
  Cases (n = 11)    0    1 (9.1)    6 (54.6)  4 (36.4)  0  0
  Controls (n = 28)    2 (7.1)    7 (25.0)  16 (57.1)  3 (10.7)  0  0
Skin 
  Cases (n = 14)    0  10 (71.4)    4 (28.6)  0  0  0
  Controls (n = 35)    1 (2.9)  17 (48.6)  14 (40.0)  3 (8.6)  0  0
Thorax 
  Cases (n = 15)    6 (40.0)    3 (20.0)    6 (40.0)  0  0  0
  Controls (n = 41)  14 (34.2)  12 (29.3)    8 (19.5)  7 (17.1)  0  0
Other Sites† 
  Cases (n = 15)  12 (80.0)    0    3 (20.0)  0  0 0
  Controls (n = 38)  19 (50.0)    9 (23.7)    6 (15.8)  4 (10.5)  0  0
Late toxicity grade‡
0 1 2 3 4 5
Bone
  Cases (n = 11) 11 (100.0) 0 0 0 0 0
  Controls (n = 28) 27 (96.4) 1 (3.6) 0 0 0 0
Breast
  Cases (n = 8)   5 (62.5) 1 (12.5) 2 (25.0) 0 0 0
  Controls (n = 20) 13 (65.0) 4 (20.0) 3 (15.0) 0 0 0
Head and neck 
  Cases (n = 12)   6 (50.0) 2 (16.7) 2 (16.7) 2 (16.7) 0 0
  Controls (n = 32) 24 (75.0) 2 (6.3) 2 (6.3) 3 (9.4) 1 (3.1) 0
Pelvis 
  Cases (n = 11)   4 (36.4) 2 (18.2) 1 (9.1) 1 (9.1) 2 (18.2) 1 
(9.1)
  Controls (n = 28) 21 (75.0) 2 (7.1) 3 (10.7) 2 (7.1) 0 0
Skin 
  Cases (n = 14) 10 (71.4) 4 (28.6) 0 0 0 0
  Controls (n = 35) 35 (100.0) 0 0 0 0 0
Thorax 
  Cases (n = 15)  11 (73.3)  1 (6.7)  2 (13.3)  1 (6.7)  0  0
  Controls (n = 41) 36 (87.8) 4 (9.8) 1 (2.4) 0 0 0
Other Sites† 
  Cases (n = 15) 14 (93.3) 0 0 0 0 1 
(6.7)
  Controls (n = 38) 36 (94.7) 0 0 2 (5.3) 0 0
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, 
and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† Other sites included the abdomen, central nervous system, extremities, and total body.
‡ Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the 
RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity 
scoring schema.20
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Toxicity by Irradiated Site
Although overall there was no significant difference noted with regard 
to the incidence of acute toxicity, CVD patients treated with RT to 
some anatomic sites were found to have a higher rate of severe acute 
toxicity (Table 2). RT to CVD patients produced higher crude rates of 
grade 3 acute toxicity when delivered to the breast (2 patients [25%] 
vs 0 patients [0%]) or pelvis (4 patients [36%] vs 3 patients [11%]). 
For the 2 CVD patients with severe breast acute toxicity, toxicity 
consisted of grade 3 skin desquamation. For the 4 CVD patients with 
severe pelvic acute toxicity, 3 had grade 3 skin desquamation alone, 
whereas the fourth patient had grade 3 skin desquamation, cystitis, 
and diarrhea/dehydration. However, given the small sample sizes 
per group and the matched case-control design of the study, formal 
statistical comparisons were not attempted. 
RT to several anatomic sites produced a higher crude rate of any 
late toxicity in CVD patients (Table 2), including the head and neck
(6 patients [50%] vs 8 patients [25%]), pelvis (7 patients [64%] vs 
7 patients [25%]), skin (4 patients [29%] vs 0 patients [0%]), and 
thorax (4 patients [27%] vs 5 patients [12%]). The incidence of severe 
toxicity was greater mainly only in the pelvis subgroup, with 4 CVD 
patients (36%) experiencing grade 3+ toxicity (consisting of small bowel 
ulceration and dysuria), including 1 grade 5 event (intestinal perforation), 
versus 2 in the control group with severe toxicity (7%). RT to the other 
anatomic sites was found to be equally well tolerated by both CVD and 
control patients.
Toxicity by CVD Subtype
Table 3 summarizes the toxicity information when separated by CVD 
subtype. The only patients who had an appreciably higher crude incidence 
of any acute toxicity when compared with controls were patients with SLE 
(88.2% vs 76.2%). Patients with SLE were also the only CVD subset found 
to have a higher crude risk of severe acute toxicity (29.4% vs 11.9%), 
which was the highest rate of severe acute toxicity noted among all CVD 
subtypes. Otherwise, severe acute toxicity was uncommon. 
Compared with controls, the incidence of any late toxicity was observed 
to be higher in several CVD subtypes: RA (29.7% vs 13.9%), SLE (41.2% 
vs 19.1%), dermatomyositis/polymyositis (16.7% vs 8.3%), polymyalgia 
rheumatica/temporal arteritis (28.6% vs 5.0%), and MCTD/other (50.0% 
vs 16.7%). The incidence of severe late toxicity was generally low among 
both CVD and control patients; however, patients with SLE (35.3% vs 
4.8%) and scleroderma (10.0% vs 3.9%) had a higher risk of severe late 
toxicity versus controls.
Concomitant Medication Use by CVD Patients
Table 4 lists several types of medications and their frequencies of use 
by CVD patients. Tables 5 and 6 list the distribution of acute and late 
toxicities for CVD cases, respectively. None of the following medications 
was found to be significantly associated with a risk of any acute or late 
toxicity: corticosteroids, NSAIDs, statins, CCBs, and antimalarials. The 
use of oral cytotoxic, rheumatologic agents was found to be significantly 
associated with a decreased risk of any acute toxicity (P = .0263), and 
concurrent infusional chemotherapy was found to be significantly 
associated with an increased risk of severe acute toxicity (P = .0022). 
Chemotherapy was the only concomitant medication that was found to 
be associated with increased risk of any (P = .009) or severe (P = .009) 
late toxicity.
Discussion
Delivering RT to patients with CVD continues to be a challenging clinical 
dilemma for radiation oncologists. The existing literature is difficult to 
interpret because of the heterogeneity in CVD subtype and activity, the 
variations in RT dose and site of treatment, as well as the potential role 
of concomitant medications in altering toxicity. Morris and Powell11 
reported that severe late effects were associated with CVD other than 
Table 3. Distribution of Toxicity (Percent) by CVD Case/Control Status, by CVD Subtype
                                                       Acute*                                                                                                      Late                                           
                            Any                                            Severe                                       Any                                       Severe             
CVD Subtype CVD Control CVD Control CVD Control CVD Control
Rheumatoid arthritis  64.9  76.2  10.8  9.9  29.7  13.9  2.7  4.0
Systemic lupus erythematosus  88.2  76.2  29.4  11.9  41.2  19.1  35.3  4.8
Dermatomyositis/polymyositis  66.7  91.7  0  8.3  16.7  8.3  0  0
Ankylosing spondylitis  0 0 0 0 0 0 0 0
Wegener granulomatosis 100  100  0  16.7  33.3  33.3 0  0
Scleroderma  30.0  53.9 0  11.5  20.0  15.4  10.0  3.9
Polymyalgia rheumatica/temporal arteritis  85.7  80.0  0  10.0  28.6  5.0  0  5.0
Mixed connective tissue disorder/other  50.0  83.3  0  16.7  50.0  16.7  0  0
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20
†
Table 4. Medications and Frequency of Use for CVD Patients
Cases (n = 86)
Medication Frequency Percentage
NSAIDs  34  39.5
Corticosteroids  32  37.2
Antimalarials  25  29.1
CCB  20  23.2
Chemotherapy*  18  20.9
Oral cytotoxic, antirheumatic drugs  17  19.8
Statins  13  15.1
CVD indicates collagen vascular disease; NSAIDs, nonsteroidal antiinflammatory drugs; CCB, calcium-
channel blocker.
* Concurrent with radiotherapy.
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Table 6. 
Medications and Treatments by Late Toxicity*: CVD Cases Only
Toxicity Grade Any Severe
Frequency
(percent) 0 1 2 3 4 5 P† P†
Corticosteroids
   No
   Yes
 37 (68.5)  6 (11.1)  5 (9.3)  3 (5.6)  2 (3.7)  1 (1.9)
 24 (75.0)  4 (12.5)  2 (6.3)  1 (3.1)  0  1 (3.1)  .63  .70
NSAIDS
   No
   Yes
 37 (71.2)  5 (9.6)  6 (11.5)  3 (5.8)  0  1 (1.9)
 24 (70.6)  5 (14.7)  1 (2.9)  1 (2.9)  2 (5.9)  1 (2.9)  ˜1  .71
Statins
   No
   Yes
 52 (71.2)  8 (11.0)  6 (8.2)  3 (4.1)  2 (2.7)  2 (2.7)
   9 (69.2)  2 (15.4)  1 (7.7)  1 (7.7)  0  0   ˜1  ˜1
CCB
   No
   Yes
 47 (71.2)  7 (10.6)  6 (9.1)  4 (6.1)  0  2 (3.0) 
 14 (70.0)  3 (15.0)  1 (5.0)  0  2 (10.0) 0   ˜1  ˜1
Antimalarials
   No
   Yes
 45 (73.8)  6 (9.8)  6 (9.8)  3 (4.9)  0  1 (1.6)
 16 (64.0)  4 (16.0)  1 (4.0)  1 (4.0)  2 (8.0)  1 (1.0)  .44  .22
Oral cytotoxics
   No
   Yes
 48 (69.6)  7 (10.1)  7 (10.1)  4 (5.8)  2 (2.9)  1 (1.5) 
 13 (76.5)  3 (17.6)  0  0  0  1 (5.9)  .77  ˜1
Infusional 
chemotherapy
   No
   Yes
 53 (77.9)  8 (11.8)  4 (5.9)  2 (2.9)  0  1 (1.5)
   8 (44.4)  2 (11.1)  3 (16.7)  2 (11.1)  2 (11.1)  1 (5.6)  .0087  .0089
CVD indicates collagen vascular disease; NSAIDs, nonsteroidal anti-inflammatory drugs; CCB, calcium-
channel blocker.
* Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the RTOG/
European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring schema.20
† P value was derived using the Fisher exact test.
Table 5. 
Medications and Treatments by Acute Toxicity*: CVD Cases Only
Toxicity Grade Any Severe
Frequency
(percent) 0 1 2 3 P† P†
Corticosteroids
   No
   Yes
  22 (40.7)  11 (20.4)  14 (25.9)  7 (13.0)
    8 (25.0)    8 (25.0)  14 (43.8)  2 (6.3)  .17 .47
NSAIDS
   No
   Yes
 17 (32.7)  11 (21.2)  18 (34.6)  6 (11.5)
 13 (38.2)    8 (23.5)  10 (29.4)  3 (8.8) .65 ˜1
Statins
   No
   Yes
 28 (38.4)  13 (17.8)  23 (31.5)  9 (12.3)
   2 (6.7)    6 (46.2)    5 (38.5)  0  .13  .34
CCB
   No
   Yes
 23 (34.9)  15 (22.7)  21 (31.8)  7 (10.6)
   7 (35.0)    4 (20.0)    7 (35.0)  2 (10.0) ˜1 ˜1
Antimalarials
   No
   Yes
 24 (39.3)  13 (21.3)  19 (31.2)  5 (8.2)
   6 (24.0)    6 (24.0)    9 (36.0)  4 (16.0)   .22  .44
Oral cytotoxics
   No
   Yes
 20 (29.0)  16 (23.2)  25 (36.2)  8 (11.6)
 10 (58.8)    3 (17.7)    3 (17.7)  1 (5.9) .026  .68
Infusional 
chemotherapy
   No
   Yes
 23 (33.8)  19 (27.9)  23 (33.8)  3 (4.4)
   7 (38.9)    0    5 (27.8)  6 (33.3)  .78  .0022
CVD indicates collagen vascular disease; NSAID, nonsteroidal anti-inflammatory drug; CCB, calcium-
channel blocker.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, 
and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† P value was derived using the Fisher exact test.
RA, a finding that was also supported by a meta-analysis by Chon and 
Loeffler.12 Other studies suggest that a diagnosis of scleroderma13,14 or 
lupus15 may increase the risk of RT associated toxicity. However, 2 separate 
matched control studies failed to observe any increased risk of acute or
late complications in patients with CVD versus patients without CVD.9,10 
To our knowledge, the current study is the largest matched-control 
analysis of acute and late complications in patients with CVDs receiving 
RT. Unlike the other matched control studies,9,10 we did find that a 
diagnosis of a CVD increased the risk of having any late toxicity, with a 
trend toward increased severe late toxicity. We also examined a variety 
of factors that can potentially influence the toxicity profile. We found 
that there was little difference in toxicity profile for most irradiated 
sites. However, RT to the breast and pelvis were possible exceptions. 
Greater than one-third of all patients with RT to the pelvis experienced 
severe acute and late toxicity. Similar to previous studies,11–15 we also 
found that patients with scleroderma or SLE were at the highest risk 
of experiencing severe acute or late complications. Morris and Powell11 
previously examined the impact of various medications on RT toxicity 
and found that patients undergoing NSAID therapy at the time of RT 
had a lower risk of late effects. Our findings demonstrated that most 
commonly used medications did not influence RT toxicity, but that 
concurrent chemotherapy was associated with increased severe acute 
and late toxicity.
There are strengths and limitations to the current study. Similar to 
previous publications on the subject, we were limited by the heterogeneity 
of CVD subtype, which thereby limited the number of patients analyzed 
for each subtype. Toxicity data was collected retrospectively, and there 
was no reliable method with which to assess CVD activity status at the 
time of RT. We were unable to analyze dose independently as a variable. 
Because dose was dependent on treatment site, it would require a range 
of RT doses at a given site and a reasonable sample size to make dose-
specific comments. This was beyond the scope of our institutional patient 
experience. The strengths of this study lie in the total number of patients 
analyzed and the use of a 3:1 control:case match by age, sex, RT dose, and 
anatomic site. This approach allows for a more robust analysis of the risk 
profile, allowing us to determine that patients with scleroderma and SLE 
are at increased risk of severe toxicity. Although other CVD subtypes may 
also predispose to toxicity, the same conclusions cannot be made because 
of the limited sample size of patients with these subtypes in our study. It 
is also important to note that with a median follow-up of 1.3 years, the 
toxicity rates reported in our study may be underestimating the true rate 
of late toxicity. Another unique aspect of this study is the comprehensive 
analysis of concomitant medication use and its impact on the RT toxicity 
profile. Given the heterogeneity observed in CVD subtype and disease 
activity, and other variables such as RT dose and site, it is not likely that 
we will ever have prospective controlled data for these questions.
In summary, although a diagnosis of a CVD appears to predispose patients 
to a greater risk of late RT toxicity, treatment is generally well tolerated, 
with a relatively low incidence of severe acute or late toxicity. Other factors 
can impact the risk of toxicity, including CVD subtype, site of irradiation, 
RT dose, and the use of concurrent chemotherapy. In patients who may 
be at particularly high risk because of CVD subtype or RT site, careful 
attention to issues of toxicity is required. Treatment modifications such as 
reduction of fraction size, twice-daily treatment, or reduction of total dose 
for these patients may be considered. These factors should be taken into 
consideration in the risk-benefit analysis at the time of consultation.
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